



Diabetes mellitus and cardiovascular risk



Next Generation Antimicrobials




Precision Medicine



Fight Against Cancer



Keynote US Health Reform



Molecular Scissors

1

A LEADING GLOBAL HEALTHCARE & LIFE SCIENCE EVENT

2016

New York City, October 27, 2016

Alexandria Center For Life Science
450 East 29th Street, between 1st Avenue and the East River, NYC



IN THE PROGRAM:

07:15 – 07:45 am

Registration and Coffee

07:45 – 08:00 am

Welcome

08:00 – 09:15 am

Diabetes mellitus and cardiovascular risk – on the rise, fall and novel possibilities with glucose lowering drugs

Bengt Samuelsson, MD, PhD, *Chair*, Nobel Laureate, Former President of Karolinska Institute and Former chairman of the Nobel Foundation

Daniel J. Drucker, Senior Scientist, Lunenfeld Tanenbaum Research Institute Mt. Sinai Hospital Toronto Ontario, Canada

Michael Mark, Vice President and Global Head of Cardio Metabolic Diseases Research Boehringer Ingelheim Pharma GmbH & Co. KG Research

Lars Rydén, MD, Dr h.c., HMRCF, FESC, FACC, FAHA, Senior Professor of Cardiology at Karolinska Institute, Stockholm, Sweden

Bernard Zinman, MD, Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and Director of the Leadership Sinai Centre for Diabetes. Mount Sinai Hospital, Toronto, Ontario

09:15 – 10:20 am

Next Generation Antimicrobials – Shaping Policy to Develop New Business Models

Joel S. Marcus, *Co-Moderator*, Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments; Co-Founder, Alexandria Summit

Lynne Zydowsky, PhD, *Co-Moderator*, President & Co-Founder, Alexandria Summit; Chief Science Advisor to the CEO, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Michael W. Bonney, Retired Chief Executive Officer, Cubist Pharmaceuticals Inc.; Advisor, UK Review on Antimicrobial Resistance

Maria C. Freire, PhD, President & Executive Director, Foundation for the National Institutes of Health

Jonathan S. Leff, MBA, Partner, Deerfield Management; Chairman, Deerfield Institute

Mark McClellan, MD, PhD, Director, Duke-Robert J. Margolis Center for Health Policy & Robert J. Margolis Professor of Business, Medicine, and Health Policy, Duke University

10:20 – 10:45 am

Coffee Break

10:45 – 11:50 am

Precision Medicine: Delivering on the Promise

Mikael Dolsten, MD, PhD, *Chair*, President, Worldwide Research and Development, Pfizer Inc.

David Feltquate, MD, PhD, Vice President, Immuno-Oncology Development, Bristol-Myers Squibb

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center

Jonathan Sheldon, PhD, Global Vice President, Healthcare, Health Sciences Global Business Unit, Oracle

Philip Vickers, PhD, Global Head of Research and Development, Shire plc

11:50 am – 12:55 pm

Promise - and Politics - in the Fight Against Cancer

Craig Thompson, MD, *Chair*, President and CEO, Memorial Sloan-Kettering Cancer Center David Epstein, division head, Novartis Pharmaceuticals

David Epstein, Former CEO and Division Head Novartis Pharmaceuticals

Margaret A. Hamburg, MD, Former Commissioner of the U.S. Food and Drug Administration

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology

12:55 – 01:45 pm

Lunch Break

01:45 – 02:45 pm

Keynote

Mark McClellan, MD, PhD, Director, Duke-Robert J. Margolis Center for Health Policy & Robert J. Margolis Professor of Business, Medicine, and Health Policy, Duke University

P. Roy Vagelos, MD, Chairman of Regeneron Pharmaceuticals and Retired Chairman and Chief Executive Officer of Merck & Co., Inc. will introduce Dr. McClellan and moderate an audience Q&A on the next chapter in the global politics of health care

02:45 – 03:50 pm

Molecular Scissors: What Can We Expect from Gene Editing?

George Yancopoulos, MD, PhD, *Chair*, Chief Scientific Officer of Regeneron Pharmaceuticals and President, Regeneron Laboratories

Charles Albright, CSO, Editas

John Leonard, CMO, Intellia Therapeutics

Sandy Macrae, President and CEO, Sangamo BioSciences